We report here the main MRI findings of a dose escalation phase 1 clinical trial with intravenous administration of theranostic AGuIX nanoparticles, conducted in 15 patients with brain metastases with the objective of evaluating the efficacy of the nanoparticles as contrast agent and radiosensitizer for brain metastases. The nanoparticles were found to enhance four different histological types of brain metastases up to one week after nanoparticle administration. Quantitative measurements of nanoparticle concentration in all types of brain metastases were obtained two hours after administration to patient - and incidentally two hours before the first session of whole brain radiotherapy.
This abstract and the presentation materials are available to members only; a login is required.